Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson's disease via m6A-dependent regulation of ATM mRNA

Fig. 1

The m6A level of dopaminergic neurons significantly reduced in PD models in vitro and in vivo. A Cell viability of mouse MN9D dopaminergic neurons treated with different concentrations of MPP + for 24 h (n = 3). B Western blotting analysis of TH and α-Syn protein expressions in the MN9D dopaminergic neurons treated with 500 μM MPP + for 24 h. C Flow cytometry analysis of apoptosis of MN9D dopaminergic neurons treated with 500 μM MPP + or not for 24 h (n = 3). D Detection of the total RNA m6A methylation levels in the MN9D dopaminergic neurons treated with 500 μM MPP + for 24 h (n = 3). E Morris water maze assay analysis of the Control and PD mice (n = 6). F IHC analysis of α-Syn in the striatum of mice PD model (n = 3). G Immunofluorescence staining analysis of dopaminergic neuronal apoptosis in the striatum of mice PD model (n = 3). H IHC analysis of m6A in the striatum of mice PD model (n = 3). Data are represented as mean ± SD, *represents P < 0.05, **represents P < 0.01

Back to article page